TP53 and acute myeloid leukemia: Preclinical studies with Nutlin 3a, as well as studies conducted by our group with patient samples from the first clinical trial with an analog of Nutlin 3a, have shown that consistent with their mechanism of action, Nutlin 3a and its analogs activate apoptosis program in acute myeloid leukemia (AML) cells only in the context of intact p53.[4, 5]